EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSFCAG00000011846
Gene Symbol: GRIK2
5 Cross references
333 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSFCAG00000005150
Gene Symbol: GRIK3
5 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSFCAG00000003358
Gene Symbol: GRIK4
3 Cross references
262 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSFCAG00000012730
Gene Symbol: GRIK5
5 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSFCAG00000006422
Gene Symbol: GRM2
5 Cross references
281 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSFCAG00000024012
Gene Symbol: GRM3
5 Cross references
213 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSFCAG00000015349
Gene Symbol: GRM4
5 Cross references
266 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSFCAG00000035511
Gene Symbol: GRM5
5 Cross references
278 Possible Orthologues:

Glutaminase

Ensembl ID : ENSFCAG00000028164
Gene Symbol: GLS
5 Cross references
306 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSFCAG00000030846
Gene Symbol: GSK3A
5 Cross references
259 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSFCAG00000040420
Gene Symbol: GSK3B
5 Cross references
244 Possible Orthologues:

Glycoprotein Vi Platelet

Ensembl ID : ENSFCAG00000029640
Gene Symbol: GP6
4 Cross references
136 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).